Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Short term Debt (2023 - 2024)

Oramed Pharmaceuticals' Short term Debt history spans 2 years, with the latest figure at $32.0 million for Q1 2024.

  • For Q1 2024, Short term Debt changed N/A year-over-year to $32.0 million; the TTM value through Mar 2024 reached $32.0 million, changed N/A, while the annual FY2023 figure was $51.0 million, N/A changed from the prior year.
  • Short term Debt reached $32.0 million in Q1 2024 per ORMP's latest filing, down from $51.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $75.4 million in Q3 2023 to a low of $32.0 million in Q1 2024.